Quantum-Si Reports Strong Growth in Q1 2025

Quantum-Si Incorporated ( (QSI) ) has released its Q1 earnings. Here is a breakdown of the information Quantum-Si Incorporated presented to its investors.

Quantum-Si Incorporated, known as The Protein Sequencing Company™, is a leader in the proteomics industry, focusing on advancing research, drug discovery, and diagnostics through its innovative protein sequencing technologies.

In its first quarter of 2025, Quantum-Si reported significant progress with an 84% increase in revenue compared to the previous year, reaching $842,000. The company also launched its Platinum® Pro units and announced the development of new library preparation kits, underscoring its commitment to innovation in proteomics.

Key financial metrics from the quarter include a gross profit of $486,000 with a gross margin of 58%. Despite a net loss of $19.2 million, the company successfully raised $50 million through a direct offering, bolstering its cash reserves to $232.6 million. Quantum-Si is also expanding its international channel network, now comprising 23 partners, to enhance its global market presence.

Looking ahead, Quantum-Si remains optimistic about its growth prospects, particularly in international markets and the pharmaceutical and biotech sectors. The company is on track with its product development roadmap, including the anticipated launch of its version 4 Sequencing Kit and the Proteus™ Platform by the end of 2025, reinforcing its strategic focus on long-term opportunities in the proteomics field.